Investors see great potential in Polyneuron
The Basel-based company Polyneuron Pharmaceuticals extended its Series A funding round and has now raised a total of 36.5 million Swiss francs. Investors also helped the company be included on a list of the 25 most promising Swiss startups that are older than five years.
Polyneuron Pharmaceuticals has concluded the extension of its Series A financing round. With further investment of 14 million francs, the startup has therefore raised a total of 36.5 million francs, as was reported in a press release. A new addition to the consortium of investors was the Swiss investment firm HBM Healthcare Investments. Existing investors include the French venture capital firm Sofinnova Partners, the U.S. venture capital firm New Enterprise Associates and other private investors.
Polyneuron will use the proceeds to advance its lead product candidate, PN-1007. This was developed as a treatment for anti-MAG neuropathy, an autoimmune disease. Patients with anti-MAG neuropathy predominantly suffer from sensory loss in their arms and legs, neuropathic pain and a loss of coordination that can substantially impair mobility. With progression of the disease, peripheral nerves suffer ever more damage. PN-1007 was designed to target the autoantibodies that cause the disease.
Polyneuron will also use the funding to progress a second program, PN-1018. This candidate is being studied for the treatment of Guillain-Barré Syndrome and Multifocal Motor Neuropathy.
In addition to concluding the financing round, Polyneuron has enjoyed another success: the company was included in a list compiled by Venturelab of the 25 most promising Swiss startups that are aged five years or more. The startup was selected by a jury of investors. According to Venturelab, these 25 companies represent the future of Swiss unicorns, startup companies with a value of more than US$ 1 billion.
Polyneuron has its headquarters in the Technologiepark Basel. The company was supported by the accelerator and incubator BaseLaunch.
Share this article
You may also be interested in
VectivBio sold for approximately 1 billion dollars
The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...Read More
University of Basel and RocketVax present new Covid vaccine
Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...Read More
Rami Swiss and Elbit Systems now manufacturing in Jura
The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...Read More
Basel to become Europe’s Silicon Valley of biotech
Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....Read More
Roche and Novartis among global leaders for research spending
In 2022, Roche invested 16 billion euros in research and development overall. This puts the Basel-based life sciences firm in...Read More
Roche to found Institute for Human Biology
Roche has announced that it will be establishing the Institute of Human Biology in Basel. Up to 250 employees will...Read More